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Abstract: Background: This study monitored total anti-SARS-CoV-2 (severe acute respiratory 
syndrome coronavirus 2) RBD (receptor-binding domain) antibodies levels in a large population 
of healthcare workers undergoing mRNA COVID-19 vaccination. Methods. The study population 
consisted of employees of Pederzoli Hospital of Peschiera del Garda (Verona, Italy), who under-
went voluntary vaccination with two doses of COVID-19 mRNA BNT162b2 (Comirnaty; Pfizer 
Inc). Venous blood was drawn immediately before the first vaccine dose, as well as 21 days (im-
mediately before second vaccine dose) and 50 days afterwards. Humoral response was assessed 
with Roche Elecsys Anti-SARS-CoV-2 S total antibodies, on Roche Cobas 6000 (Roche Diagnos-
tics). Results: The final study population consisted of 925 subjects (mean age, 44±13 years; 457 
women), 206 (22.3%) anti-SARS-CoV-2 baseline seropositive. The increase of total an-
ti-SARS-CoV-2 RBD antibodies levels 21 days after the first vaccine dose was ~3 orders of magni-
tude higher in seropositive than in seronegative individuals (11782 vs. 42 U/mL; p < 0.001). Total 
anti-SARS-CoV-2 RBD antibodies levels further increased by over 30-fold after the second vaccine 
dose in baseline seronegative subjects, while such increase was only ~1.3-fold in baseline seroposi-
tive subjects. In multivariate analysis, total anti-SARS-CoV-2 RBD antibodies level was inversely 
associated with age after both vaccine doses and male sex after the second vaccine dose in baseline 
seronegative subjects, while baseline antibodies value significantly predicted immune response 
after both vaccine doses in baseline seropositive recipients. Conclusion: Significant difference ex-
ists in post-mRNA COVID-19 vaccine immune response in baseline seronegative and seropositive 
subjects, which seems dependent on age and sex in seronegative subjects, as well as on baseline 
anti-SARS-CoV-2 antibodies level in seropositive patients. 
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1. Introduction 
One and two decades after the two last coronavirus outbreaks sustained by severe 
acute respiratory syndrome coronavirus (SARS-CoV) and Middle-East respiratory syn-
drome coronavirus (MERS-CoV), respectively, a new coronavirus disease has emerged, 
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reaching pandemic proportions [1]. Coronavirus disease 2019 (COVID-19), caused by 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), generates a wide spec-
trum of clinical manifestations, from asymptomatic infection to severe lower respiratory 
tract involvement (with interstitial pneumonia), then progressing toward severe sys-
temic disease and development of multiple organ failure in patients with severe illness, 
up to death [2]. Owing to the nearly unstoppable worldwide diffusion of SARS-CoV-2, 
several preventative and containing measures have been adopted. Besides physical in-
terventions, such as social distancing, widespread use of face masks, hand hygiene and 
timely isolation of infected and infectious subjects, universal vaccination is now regard-
ed as the most effective strategy to limit the clinical, societal and economic consequences 
of COVID-19 around the world [3]. 
Vaccines mainly act by simulating a natural infection, and thereby promoting de-
velopment of a humoral and cellular immune response aimed at defending the host 
against a specific pathogen. As specifically concerns COVID-19, unprecedented efforts 
have been underway to develop efficient vaccine formulations primarily aimed at re-
ducing the risk of developing aggressive forms of disease, and hence preventing 
healthcare system collapse, as well as for limiting the encumbrance of asymptomatic in-
fections, which may still actively contribute to sustain viral circulation within the com-
munity [4]. Several strategies are being pursued, thus encompassing vaccines based on 
inactivated virus, viral proteins (e.g., spike protein), as well as DNA- and mRNA-based 
vaccines [5].  
The last generation of lipid-based mRNA-lipid nanoparticles vaccines 
(mRNA-LNPs) was found to be especially convenient, since they conjugate many tech-
nical, biological and clinical advantages [6]. The major technical advantages of these 
mRNA-LNPs are represented by their ability to closely reproduce natural viral infection 
without delivering viral particles (mRNA penetrates the host cells and is translated into 
antigen viral proteins mounted at cell surface or released in the surrounding environ-
ment), the potentially lower immunogenicity and cytotoxicity of nanoparticles, the ca-
pability to deliver multimeric antigens which may hence allow the rapid reengineering 
of the formulation with inclusion of new polymorphisms [7,8]. With respect to the bio-
logical aspects, the currently used mRNA-LNPs contain genetic material encoding a re-
combinant form of SARS-CoV-2 spike protein with its receptor-binding domain (RBD), 
and are hence effective to stimulate B cells to generate neutralizing antibodies directed 
against the spike protein, thus reducing binding effectiveness with receptors at the host 
cell surface (especially with angiotensin converting enzyme 2; ACE2), and enhancing 
virus inactivation and clearance. A sustained generation of anti-SARS-CoV-2 T cells is 
also likely elicited (especially CD4+ and CD8+ cells), and would work to eliminate in-
fected cells [9]. These two convergent pathways synergistically contribute to mitigate the 
clinical impact of SARS-CoV-2, as attested by recent evidence reviewed by Abdool Ka-
rim and de Oliveira [10], showing that mRNA-LNPs may display 94–95% efficiency in 
preventing SARS-CoV-2 infection and 90–100% efficacy in averting severe COVID-19 
illness. Nonetheless, concerns have been expressed that the immune response after ad-
ministration of these mRNA-LNPs may be characterized by high inter-individual varia-
tion, with some people developing higher titers of neutralizing antibodies compared to 
others who may only have a “mild” and thus less efficient response [11–13]. Therefore, 
this retrospective observational study was aimed to monitor the anti-SARS-CoV-2 RBD 
total antibodies response in a large population of healthcare workers, both SARS-CoV-2 
seropositive and seronegative, undergoing voluntary mRNA vaccine administration. 
2. Materials and Methods 
The study population consisted of the entire sanitary and administrative staff of the 
Pederzoli Hospital of Peschiera del Garda (Verona, Italy), who underwent voluntary 
vaccination with COVID-19 mRNA-LNP BNT162b2 (Comirnaty; Pfizer Inc, NY, USA). 
The first 30 μg vaccine dose was administered between January 4 and 15, 2021, followed 
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by a second 30 μg vaccine dose 21 days exactly after the first dose. Both vaccine doses 
were prepared strictly following manufacturer’s instruction and administered to all 
study participants within 30 min from resuspension. No subjects had taken immuno-
suppressive drugs immediately before vaccination. Venous blood was drawn in the 
morning by straight needle venipuncture into evacuated blood tubes containing gel and 
clot activator (Greiner Bio-One, Kremsmünster, Austria) 15 min before administration of 
the first vaccine dose, as well as 21 (immediately before 2nd dose vaccination) and 50 
days afterwards. Blood samples were transported to the local core laboratory, where 
they were separated by centrifugation for 15 min at 1500× g at room temperature. Serum 
was separated from the underlying cellular pellet, divided in 2 identical aliquots of ~1.5 
mL and stored at −70°C until measurement. Therefore, all subjects were prospectively 
enrolled for vaccination, according to national guidelines, and then samples were retro-
spectively analyzed. The paired aliquots collected at different time points from each par-
ticipant were concurrently thawed at the end of the study period, centrifuged and ana-
lyzed with the novel Roche Elecsys Anti-SARS-CoV-2 S immunoassay on a Roche Cobas 
6000 (Roche Diagnostics, Basel, Switzerland). This one-step double antigen sandwich 
assay has been developed for quantitative assessment of total anti-SARS-CoV-2 RBD an-
tibodies in human serum and plasma specimens. Briefly, the patient sample is incubated 
with a mix of biotinylated and ruthenylated SARS-CoV-2 RBD recombinant antigen. 
Double antigen sandwich immune complexes are eventually formed when the corre-
sponding antibodies are present. After addition of streptavidin-coated microparticles, 
double antigen sandwich immune complexes bind to the solid phase through interaction 
of biotin and streptavidin. The reagent mix is then transferred to the measuring cell, 
where microparticles are magnetically captured onto the electrode surface. Unbound 
material is removed and electrochemiluminescence is applied and measured with a 
photomultiplier. The signal yield is proportional to total anti-SARS-CoV-2 RBD anti-
bodies level present in the test sample. According to manufacturer’s declaration, this test 
displays 92% (95% CI, 64–100%) positive agreement with a virus pseudo-neutralization 
assay and 100% diagnostic specificity and 89% diagnostic sensitivity for detecting 
SARS-CoV-2 infection 14 days after symptoms onset. The limit of blank (LoB) and limit 
of detection (LoD) are 0.30 U/mL and 0.40 U/mL, respectively, the linearity is between 
0.40–250 U/mL (extensible to 2500 U/mL with 1:10 sample dilution), and the total impre-
cision is between 1.4–2.4%. Test results <0.8 U/mL are classified as non-reactive, while 
those ≥0.8 U/mL are classified as reactive. A recent clinical evaluation of this novel im-
munoassay found excellent performance, with 97.9% and 100% positive agreement with 
molecular testing >14 days and >21 days after symptoms onset, respectively, combined 
with 99.9% negative agreement [14].  
All subjects participating to this retrospective observational study gave two sepa-
rate written informed consents for both receiving vaccination and being included in the 
serological monitoring survey. This retrospective observational study was conducted in 
accordance with the Declaration of Helsinki and the protocol cleared by the Ethics 
Committee of the Provinces of Verona and Rovigo (3246CESC). 
Statistical analysis 
The results of total anti-SARS-CoV-2 RBD antibodies testing were presented as me-
dian and interquartile range (IQR), and as ratio with baseline total anti-SARS-CoV-2 an-
tibodies level (i.e., [time point value]/[baseline value and/or limit of detection]). Differ-
ences between groups were assessed with Mann–Whitney U test and chi-square statis-
tics, when appropriate. Univariate relationships between antibody levels and other var-
iables (e.g., age, sex, baseline total anti-SARS-CoV-2 RBD antibody level) were assessed 
using Spearman’s correlation. Multivariable linear regression analyses were then used to 
assess these correlations for each time point (day 21 and day 50) and group (seropositive 
and seronegative). The mean difference (MD) with 95% confidence interval (95% CI) was 
calculated to quantify the difference of total anti-SARS-CoV-2 RBD antibodies levels 
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between groups. Statistical analysis was conducted with Analyse-it (Analyse-it Software 
Ltd, Leeds, UK) and MetaXL, software Version 5.3 (EpiGear International Pty Ltd., Sun-
rise Beach, Australia).  
3. Results 
The initial study population consisted of 1003 employees of the Pederzoli Hospital 
of Peschiera del Garda, who voluntarily agreed to undergo vaccination with Pfizer 
COVID-19 mRNA Vaccine Comirnaty. A total number of 78 subjects were lost during 
follow-up sampling (7 at 21 days and 71 at 50 days, respectively), such that the final 
study population consisted of 925 subjects (mean age, 44 ± 13 years; 457 (49.4%) women) 
who completed the two-dose vaccine cycle and had serum samples drawn at all the three 
time points. Two hundred and six (22.3%) subjects had measurable total an-
ti-SARS-CoV-2 RBD antibodies level (i.e., ≥0.8 U/mL) before vaccination, and were hence 
classified as baseline seropositive. The age (43 ± 13 vs. 44 ± 13 years; p = 0.206) and sex 
(70% vs. 64% females; p = 0.093) of baseline seropositive individual values did not differ 
from those of baseline seronegative subjects. The humoral immune response in both the 
seronegative and seropositive cohorts after the complete mRNA COVID-19 vaccination 
cycle is shown in Figure 1.  
 
Figure 1. Total anti-SARS-CoV-2 RBD antibodies in seronegative (<0.8 U/L) or seropositive (≥0.8 
U/L) subjects at baseline and after receiving a complete cycle (i.e., two doses) of Pfizer COVID-19 
mRNA BNT162b2 vaccine. 
The absolute increase of antibody level 21 days after the first vaccine dose was 
nearly 3 orders of magnitude higher in seropositive than in seronegative individuals 
(11782 vs. 42 U/mL; p < 0.001) (Table 1).  
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Table 1. Total anti-SARS-CoV-2 RBD antibodies levels (median and interquartile range) in sero-
negative (<0.8 U/L) or seropositive (≥0.8 U/L) subjects at baseline and after receiving a complete 







Baseline 21 Days 50 Days 
Seronegative       
- Level 
(u/mL) 
719 44 ± 13 457/719 
(64%) 
<0.8 42 (15–98) 1364 
(761–2174) 
- ≥0.8 u/mL 
(%) 
0/709 (0%) 710/719 (98.7%) 719/719 (100%) 
       
Seropositive       
- Level 
(u/mL)  












206/206 (100%) 206/206 (100%) 
While antibodies levels further increased by over 30 folds 1 month after the second 
vaccine dose in baseline seronegative subjects, the increase in baseline seropositive sub-
jects was only ~1.30-fold (Table 1). Nonetheless, 1 month after the second vaccine dose, 
baseline seropositive subjects had total anti-SARS-CoV-2 RBD antibodies levels that 
were 11-fold higher than baseline seronegative subjects (15142 vs. 1364 U/mL; p < 0.001). 
The rate of subjects reaching seropositive status after receiving the first vaccine dose was 
98.7% and 100% in baseline seronegative and seropositive recipients, respectively, in-
creasing to 100% in both cohorts 1 month after the second vaccine dose. A highly signif-
icant correlation could be found between the ratios of increase from the individual base-
line antibodies level observed after the first (21 days) and second (50 days) vaccine doses 
in both baseline seronegative (r = 0.68; 0.63 to 0.71; p < 0.001) and baseline seropositive (r 
= 0.95; 95% CI, 0.94 to 0.96; p < 0.001) recipients. 
The Spearman’s correlation between the magnitude of increase in total an-
ti-SARS-Cov-2 antibodies and age, sex, and baseline antibodies levels in baseline sero-
negative and seropositive subjects is shown in Table 2. In univariate analysis, total an-
ti-SARS-CoV-2 RBD antibodies response to the first and second vaccine doses was sig-
nificantly associated with both age and sex in the baseline seronegative cohort, while it 
was only associated with baseline antibody value in those seropositive at baseline (Table 
2). 
Table 2. Spearman’s correlation coefficient (and 95% CI) between the ratio of increase from indi-
vidual baseline total anti-SARS-CoV-2 RBD antibodies level and age, sex or baseline antibodies 
value in baseline seronegative (<0.8 U/L) and baseline seropositive (≥0.8 U/L) subjects receiving a 
complete cycle (i.e., two doses) of Pfizer COVID-19 mRNA BNT162b2 vaccine. 
Antibody 
status 
Age Sex ( males vs. females) Baseline value 
Seronegative    
- 21 days −0.33 (95%CI, −0.39 to 
−0.26; p < 0.001) 
−0.08 (95%CI, −0.15 to 
−0.01; p = 0.036) 
N/A 
- 50 days −0.27 (95%CI, −0.33 to 
−0.20; p < 0.001) 
−0.16 (95%CI, −0.23 to 
−0.09; p < 0.001) 
N/A 
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Seropositive    
- 21 days −0.03 (95% CI; −0.16 to 
0.11; p = 0.680) 
0.09 (95% CI; −0.05 to 
0.23; p = 0.189) 
−0.80 (95% CI; −0.84 to 
−0.74; p < 0.001) 
- 50 days −0.05 (95% CI; −0.18 to 
0.09; p = 0.487) 
0.12 (95% CI; −0.02 to 
0.25; p = 0.096) 
−0.88 (95% CI; −0.91 to 
−0.85; p < 0.001) 
In multivariate analysis, total anti-SARS-CoV-2 RBD antibodies response remained 
significantly associated with age after both vaccine doses and with sex after the second 
vaccine dose in baseline seronegative subjects, while the baseline total anti-SARS-CoV-2 
RBD antibodies value remained significant predictor of response after both vaccine dos-
es in the baseline seropositive cohort (Table 3). 
Table 3. Multivariate analysis (beta coefficient and 95% CI) of the ratio of increase from individual 
baseline total anti-SARS-CoV-2 RBD antibodies level and age, sex or baseline antibodies value in 
baseline seronegative (<0.8 U/L) and baseline seropositive (≥0.8 U/L) subjects receiving a complete 
cycle (i.e., two doses) of Pfizer COVID-19 mRNA BNT162b2 vaccine. 
Antibody 
status 
Age Sex (males vs. females) Baseline value 
Seronegative    
- 21 days -5 (95% CI; -7 to -3; p < 
0.001) 
-10 (95% CI; -66 to 45; p < 
0.706) 
N/A 
- 50 days -565 (95% CI; -1036 to 
-93; p < 0.001) 
-51 (95% CI; -69 to -32; p 
= 0.019) 
N/A 
Seropositive    
- 21 days 0.4 (95% CI; -9.5 to 
10.4; p = 0.930) 
0.8 (95% CI; -274.4 to 
276.0; p = 0.995) 
-0.2 (95% CI; -0.4 to 
0.0; p = 0.023) 
- 50 days -1.3 (95% CI; -13.8 to 
11.3; p = 0.804) 
19.1 (95% CI; -326.2 to 
364.4; p = 0.913) 
-0.3 (95% CI; -0.5 to 
0.0; p = 0.022) 
The MD of total anti-SARS-CoV-2 RBD antibody levels among different cohorts is 
summarized in Figure 2. After the second vaccine dose, women (n = 457; 63.6%) had 292 
U/mL higher levels than men (+1.20-fold), while subjects younger than 60 years (n = 644; 
89.6%) had 38 U/mL (+1.84-fold) and 427 U/mL (+1.33-fold) higher antibody levels after 
the first and second vaccine dose, respectively, compared to older individuals (Figure 2). 
 
Figure 2. Mean difference (MD) of total anti-SARS-CoV-2 RBD antibodies in seronegative subjects 
receiving a complete cycle (i.e., two doses) of Pfizer COVID-19 mRNA BNT162b2 vaccine as cal-
culated after 21 and 50 days from the first dose. 
4. Discussion 
It seems now almost indisputable that universal COVID-19 vaccination will be the 
keystone in all strategies aimed at stopping or limiting the worldwide circulation of 
SARS-CoV-2. Nonetheless, although the efficacy of most currently licensed vaccines ap-
pears considerably high, especially at reducing the risk of clinical deterioration [15], a 
considerable inter-individual heterogeneity in post-vaccine immune response is being 
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increasingly noted in some specific populations, especially in the elderly [16] and in 
immunosuppressed patients [17,18]. Unfortunately, low vaccine responders mostly in-
clude categories of frail patients, who already have a magnified risk of unfavorable dis-
ease progression if contracting SARS-CoV-2 [19]. To this end, monitoring post-vaccine 
immune response in the population should be considered highly advisable, as also re-
cently endorsed by the International Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC) [20]. 
Overall, the identification of three important predictors (age, sex, baseline serosta-
tus) of post-COVID-19 mRNA BNT162b2 vaccine humoral response in our population of 
healthcare workers may have some substantial implications and consequences for vac-
cine plans. Unlike the recent study of Dörschug et al. [21], who used a spike pro-
tein-based IgG serological immunoassay for monitoring humoral response to COVID-19 
mRNA BNT162b2 vaccine and failed to find significant differences between sexes, we 
found that women had a significantly higher response (between 1.15–1.20-fold higher 
compared to men) of total anti-SARS-CoV-2 RBD antibodies, especially after the second 
vaccine dose. This agrees with recent data published by Terpos et al. [22], who also 
found that the anti-Spike-RBD IgGs response was more sustained in female than in male 
octogenarians after vaccination with Pfizer BNT162b2 mRNA vaccine. In keeping with 
previous reports [23–26], we also observed a gradual reduction of total anti-SARS-CoV-2 
RBD antibodies level in older individuals (i.e., aged 60 years or older). In particular, a 
significant difference by age (≤60 years vs. >60 years) could be noted after the first 
mRNA vaccine dose (~1.3-fold), which was magnified after the second dose (~1.9-fold). 
Interestingly, the highly significant correlation observed in the immune response ob-
served after the first and second vaccine doses in both baseline seronegative and base-
line seropositive recipients suggests that the final level of total anti-SARS-CoV-2 RBD 
antibodies attainable after the second vaccine dose could be reliably predicted by the 
first dose response, especially in baseline seropositive recipients. 
The lower total anti-SARS-CoV-2 RBD antibodies response found in males and old-
er baseline seronegative subjects would suggest that this specific population may have 
less efficient protection against infection and/or an even higher risk of developing more 
aggressive forms of COVID-19, such that delaying, or even abolishing, the second vac-
cine dose seems highly unadvisable [27]. Other than further safeguarding these popula-
tions from being infected by SARS-CoV-2 by encouraging public health preventative 
measures, higher and/or more frequent mRNA vaccine doses should be considered for 
boosting the immunogenicity in subjects with predictably lower response after the 
standard 2-dose mRNA vaccine cycle, as also recently underpinned by Van Praet and 
colleagues [28]. This hypothesis is already under consideration by some pharmaceutical 
companies. Pfizer has already started to test the efficacy of a third booster in people 
aged 65 to 85 years, who have received their first two doses of COVID-19 mRNA 
BNT162b2 in the phase III trial [29].  
Assuring a sustained and durable protection against SARS-CoV-2 in the community 
by vaccination is the most important tool for containing the dramatic clinical and socie-
tal effects of the ongoing SARS-CoV-2 pandemic in the face of the emergence of novel 
strains and new outbreaks. To this end, the identification of subjects with low/modest 
post-vaccine immune response will be vital for limiting the potential unfavorable impact 
of emerging SARS-CoV-2 variants (especially those bearing the so-called “immune es-
cape mutations”), ensuring adequate personal and community immune protection and 
limiting viral circulation, thereby reducing the risk that novel and even more dangerous 
mutations will accumulate [30–32]. Moreover, recent evidence of a sustained IgA re-
sponse after mRNA-LNPs vaccination [33], combined with clinical observations of de-
creased viral load in the limited number of reported cases after inoculation [34], suggests 
that these vaccines can reduce viral replication, which itself would result in decreased 
likelihood of new mutation generation in the case of asymptomatic/symptomatic 
SARS-CoV-2 infection of a vaccinated individual. 
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The influence of baseline anti-SARS-CoV-2 antibody status on post-vaccine re-
sponse of seropositive subjects (i.e., those with previous asymptomatic or symptomatic 
infection) deserves special focus. We observed enormously boosted total an-
ti-SARS-CoV-2 RBD antibodies response in baseline seropositive people, which may 
have some notable clinical implication. Several studies have now reported that the level 
of anti-SARS-CoV-2 antibodies reached after vaccination is dependent on the seronega-
tive/seropositive status at time of vaccination [35–40]. In particular, Mueller also used 
the Roche Elecsys Anti-SARS-CoV-2 S immunoassay to monitor response to BNT162b2 
COVID-19 vaccine and found that antibodies became positive in all samples 2 weeks af-
ter the first administration, with serum concentrations then constantly increasing for the 
following 4–5 weeks [41]. Although our findings are indeed in substantial agreement 
with these previous observations, we provide further evidence that the baseline anti-
body status is a very strong predictor of post-vaccine total anti-SARS-CoV-2 RBD anti-
bodies response, with high correlation after the first and second vaccine doses. Our data 
clearly show that the second vaccine dose only produced a marginal gain of antibodies 
titer (i.e., around 30%) after the first dose in our population of baseline seropositive sub-
jects. Considering the very high anti-SARS-CoV-2 RBD total antibodies levels seen after 
the first vaccine dose, the second dose is unlikely to significantly enhance protection 
against re-infections, even with different strains, and/or the risk of developing severe 
illness, at least within a 6- to 12-month window after vaccination when IgG titers will 
likely remain adequate in most. With vaccines supply remaining limited all around the 
world [42], the European Center for Disease Control and Prevention (ECDC) states that 
consideration should be given to vaccinate specific populations which may have dis-
proportionate risk of exposure or disease aggravation [43]. In keeping with this sugges-
tion, allocation of vaccine doses for those who are at high risk of severe disease should 
be a universal priority [44,45].  
Evidence is accumulating that people who have been previously infected with 
SARS-CoV-2, with either symptomatic or asymptomatic disease, may be predisposed to 
stronger reactions to vaccination, thus carrying a greater risk of developing side effects 
and/or adverse reactions [38]. This risk has been clearly acknowledged by the US Cen-
ters for Disease Control and Prevention in its ad interim clinical recommendations for 
COVID-19 vaccination [46], whereby it is now stated that people with a recent 
SARS-CoV-2 infection may choose to temporarily delay vaccination. Finally, the consid-
erably high anti-SARS-CoV-2 baseline positivity observed in our study (i.e., 22.3%) is not 
surprising, since an almost identical figure (i.e., 22.9%) has been reported in a seroprev-
alence survey recently carried out in the General Hospital of Brescia [47], which is just at 
50 km distance from Peschiera del Garda. 
5. Conclusions 
The results of this large retrospective observational study aimed at monitoring total 
anti-SARS-CoV-2 RBD antibodies response after Pfizer mRNA COVID-19 vaccination 
reveal that significant difference exists between seronegative and seropositive subjects, 
and that such response may be dependent on age and sex in seronegative subjects, as 
well as on baseline anti-SARS-CoV-2 antibodies level in seropositive patients. Future 
studies should be planned to establish whether additional demographical variables not 
included in our analysis, such as the presence of comorbidities, ethnicity, body mass in-
dex, and physical activity, may influence humoral response to mRNA-LNPs vaccination. 
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